SUPPLEMENTAL APPENDIX

Supplemental Table 1 Clinical Definitions

Supplemental Table 2 Breakdown of SARS-CoV-2 Tests

Supplemental Table 3 Selected Presenting Laboratory Values

Supplemental Table 4 Frequency of Respiratory Therapies

Supplemental Table 5 Cox Proportional Hazard Model

Table 5aIntubation

Table 5bDeath

Table 5cCombined (Intubation or Death)

Supplemental Figure 1 Distribution of Time from ED Arrival to First Intubation

Supplemental Figure 2 Days from First Symptom to First Intubation vs. ED Date

**Supplemental Table 1**

|  |  |
| --- | --- |
|  | **Definition** |
| **Complications** |  |
| Acute Kidney Injury (AKI) | As defined by clinical notes in EHR |
| Acute Respiratory Distress Syndrome (ARDS) | As defined by clinical notes in EHR (all met Berlin Criteria, not further categorized by severity) |
| **Comorbidity Groupings** |  |
| Pulmonary Disease | Documentation of any pulmonary disease in the patient’s chart as past medical history including, but not limited to asthma, Chronic Obstructive Pulmonary Disease (COPD), obstructive sleep apnea (OSA), or interstitial lung disease (ILD). |
| Renal Disease | Documentation of chronic kidney disease (CKD) or end stage renal disease (ESRD) in the patient’s chart as past medical history. |
| Rheumatological Disease | Documentation of any autoimmune disease in the patient’s chart as past medical history including, but not limited to rheumatoid arthritis or systemic lupus erythematosus (SLE), scleroderma, sarcoidosis. |

**Supplemental Table 1 Clinical Definitions** Description of the definitions used for select complications and comorbidity groupings.

**Supplemental Table 2**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All NYP/CUIMC Tests** | **Outpatient/Affiliate Tests** | **ED/Inpatient Tests** | **Our Cohort** |
| Positive SARS-CoV-2 | 1403 | 271 | 1132 | 1000 |
| Negative/Indeterminate SARS-CoV-2 | 1020 | 339 | 681 | 0 |

**Supplemental Table 2 Breakdown of SARS-CoV-2 Tests** Number of total SARS-CoV-2 tests done at NYP/CUMC (positive and negative), along with those only done in ED/Inpatient setting. Our cohort comprises the first 1000 of the 1132 SARS-CoV-2 positive patients who sought hospital care from March 1 to April 6 2020.

**Supplemental Table 3**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Lab Test** | **ED** **Median [IQR] (n)** | **Hospitalized (non-ICU) Median [IQR] (n)** | **ICU** **Median [IQR] (n)** | **Overall** **Median [IQR] (n)** |
| ALT (U/L) | 32 [23 - 55.5] (n = 59) | 28 [19 - 45] (n = 374) | 32.5 [22 - 58.25] (n = 150) | 29 [20 - 50] (n = 583) |
| AST (U/L) | 41 [26 - 82.25] (n = 60) | 37 [26 - 58] (n = 377) | 55 [34 - 86] (n = 150) | 41 [27 - 65.5] (n = 587) |
| CRP (mg/L) | 49.4 [17.36 - 156.3] (n = 29) | 100.215 [57.4475 - 155.8175] (n = 206) | 172.54 [96.47 - 239.645] (n = 99) | 110.855 [58.59 - 190.7] (n = 334) |
| Creatinine (mg/dL) | 1.055 [0.86 - 1.29] (n = 78) | 1.05 [0.83 - 1.59] (n = 452) | 1.2 [0.92 - 1.85] (n = 177) | 1.08 [0.85 - 1.595] (n = 707) |
| ESR (mm/hr) | 51 [44 - 69.5] (n = 18) | 64.5 [44 - 87] (n = 172) | 68 [54.25 - 90.5] (n = 86) | 65 [45 - 87] (n = 276) |
| Ferritin (ng/mL) | 357.15 [131.275 - 765.875] (n = 20) | 557.05 [288.825 - 985.475] (n = 166) | 1021 [556.7 - 1970] (n = 97) | 714.6 [348.6 - 1254] (n = 283) |
| D-Dimer (ug/mL FEU) | 0.82 [0.38 - 0.94] (n = 15) | 1.05 [0.705 - 1.53] (n = 119) | 1.52 [0.9575 - 2.305] (n = 68) | 1.19 [0.7025 - 1.9975] (n = 202) |
| LDH (U/L) | 386 [248 - 529.75] (n = 26) | 366 [294 - 502] (n = 179) | 504 [404.75 - 691.25] (n = 92) | 414 [318 - 551] (n = 297) |
| WBC (x10(3)/uL) | 6.46 [5.19 - 8.62] (n = 77) | 6.645 [5.0325 - 8.535] (n = 450) | 7.92 [5.58 - 10.98] (n = 181) | 6.885 [5.1575 - 9.1225] (n = 708) |
| Troponin I (ng/mL) | 0.025 [0.0075 - 0.0725] (n = 4) | 0.01 [0.01 - 0.0225] (n = 12) | 0.01 [0.01 - 0.03] (n = 13) | 0.01 [0.01 - 0.03] (n = 29) |
| hs-Troponin (ng/L) | 9 [6 - 29] (n = 45) | 14 [7 - 31] (n = 293) | 17 [9 - 49.75] (n = 136) | 15 [7 - 34.75] (n = 474) |

**Supplemental Table 3 Selected Presenting Laboratory Values** Selected laboratory values (Median and IQR) across three levels of care. ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; CRP, reactive protein; ESR, Erythrocyte sedimentation rate; LDH, Lactate dehydrogenase; WBC, White Blood Cells; hs-Troponin, Troponin High sensitivity method. All categorical data is reported as a frequency and a column percentage [95% confidence interval] along with the number of patients that had the test performed (n).

**Supplemental Table 4**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **ED**  **(n = 150)** | **Hospitalized (non-ICU)**  **(n = 614)** | **ICU**  **(n = 236)** | **Overall**  **(N = 1000)** |
| Supplemental O2 within 3 hours of ED Arrival | 29  19.3% [13.8 - 26.4] | 256  41.7% [37.9 - 45.6] | 174  73.7% [67.8 - 78.9] | 459  45.9% [42.8 - 49] |
| Nasal Canula | 15  10% [6.2 - 15.8] | 402  65.5% [61.6 - 69.1] | 143  60.6% [54.2 - 66.6] | 560  56% [52.9 - 59] |
| Non-Rebreather Mask | 14  9.3% [5.6 - 15.1] | 177  28.8% [25.4 - 32.5] | 174  73.7% [67.8 - 78.9] | 365  36.5% [33.6 - 39.5] |
| Venturi Mask | 1  0.7% [0.1 - 3.7] | 7  1.1% [0.6 - 2.3] | 10  4.2% [2.3 - 7.6] | 18  1.8% [1.1 - 2.8] |
| High Flow Nasal Canula | 0  0% [0 - 2.5] | 4  0.7% [0.3 - 1.7] | 19  8.1% [5.2 - 12.2] | 23  2.3% [1.5 - 3.4] |
| Non-invasive Ventilation (CPAP, BiPAP) | 3  2% [0.7 - 5.7] | 4  0.7% [0.3 - 1.7] | 7  3% [1.4 - 6] | 14  1.4% [0.8 - 2.3] |
| Invasive Ventilation (Intubated) | 12  8% [4.6 - 13.5] | 1  0.2% [0 - 0.9] | 220  93.2% [89.3 - 95.8] | 233  23.3% [20.8 - 26] |
| Prone Positioning | 0  0% [0 – 2.5] | 5  0.8% [0.3 – 1.9] | 48  20.3% [15.7 – 25.9] | 53  5.3% [4.1 – 6.9] |

**Supplemental Table 4 Frequency of Respiratory Therapies** Count and frequency of respiratory therapies across three levels of care. All categorical data is reported as a frequency and a column percentage [95% confidence interval].

**Supplemental Table 5a**

|  |  |  |
| --- | --- | --- |
| **Variable** | **HR (95% CI)** | **p-value** |
| Age (Numeric) | 0.996 (0.985 to 1.01) | 0.419 |
| Female | 0.714 (0.535 to 0.95) | 0.0221 |
| BMI (Numeric) | 1.02 (0.999 to 1.04) | 0.0682 |
| Current or Former Smoker | 1.05 (0.883 to 1.24) | 0.601 |
| Coronary Artery Disease | 0.858 (0.555 to 1.33) | 0.492 |
| Congestive Heart Failure | 0.812 (0.594 to 1.11) | 0.192 |
| History of Stroke | 0.96 (0.571 to 1.62) | 0.879 |
| Diabetes Mellitus | 1.12 (0.839 to 1.49) | 0.444 |
| Hypertension | 1.59 (1.1 to 2.3) | 0.0141 |
| Cirrhosis | 1.16 (0.385 to 3.5) | 0.791 |
| HIV | 1.05 (0.455 to 2.4) | 0.917 |
| Inflammatory Bowel Disease | 0.337 (0.0466 to 2.43) | 0.28 |
| Pulmonary Disease | 1.07 (0.771 to 1.48) | 0.698 |
| Renal Disease | 0.695 (0.44 to 1.1) | 0.118 |
| Viral Hepatitis | 0.942 (0.349 to 2.54) | 0.905 |
| Active Malignancy | 0.654 (0.33 to 1.3) | 0.224 |
| Transplant History | 1.03 (0.525 to 2.04) | 0.923 |
| Rheumatological Disease | 1.09 (0.54 to 2.18) | 0.816 |
| Immunosuppressed State | 0.959 (0.328 to 2.8) | 0.94 |
| No Comorbidities | 0.999 (0.562 to 1.77) | 0.997 |

**Supplemental Table 5a Cox Proportional Hazard Model for Intubation** Hazard ratio of intubation for demographics and comorbidities with 95% confidence intervals and corresponding p-values. Only patients with complete data for all of the above variables were included in the model (n = 841).

**Supplemental Table 5b:**

|  |  |  |
| --- | --- | --- |
| **Variable** | **HR (95% CI)** | **p-value** |
| Age (Numeric) | 1.07 (1.05 to 1.08) | 1.66E-19 |
| Female | 0.793 (0.576 to 1.09) | 0.155 |
| BMI | 1.02 (1 to 1.05) | 0.025 |
| Current or Former Smoker | 0.967 (0.797 to 1.17) | 0.734 |
| Coronary Artery Disease | 1.25 (0.83 to 1.89) | 0.284 |
| Congestive Heart Failure | 1.07 (0.808 to 1.42) | 0.639 |
| History of Stroke | 1.3 (0.84 to 2.01) | 0.239 |
| Diabetes Mellitus | 1.23 (0.894 to 1.68) | 0.206 |
| Hypertension | 0.89 (0.56 to 1.41) | 0.62 |
| Cirrhosis | 1.95 (0.62 to 6.17) | 0.253 |
| HIV | 2.47 (1.05 to 5.86) | 0.0393 |
| Inflammatory Bowel Disease | 1.18 (0.346 to 4.06) | 0.787 |
| Pulmonary Disease | 0.817 (0.554 to 1.2) | 0.306 |
| Renal Disease | 1.61 (1.06 to 2.43) | 0.0245 |
| Viral Hepatitis | 0.606 (0.127 to 2.89) | 0.53 |
| Cancer | 1.01 (0.554 to 1.83) | 0.98 |
| Transplant History | 0.986 (0.448 to 2.17) | 0.972 |
| Rheumatological Disease | 0.481 (0.173 to 1.34) | 0.161 |
| Immunosuppressed State | 1.57 (0.663 to 3.73) | 0.305 |
| No Comorbidities | 0.56 (0.191 to 1.64) | 0.29 |

**Supplemental Table 5b Cox Proportional Hazard Model for Death** Hazard ratio of death for demographics and comorbidities with 95% confidence intervals and corresponding p-values. Only patients with complete data for all of the above variables were included in the model (n = 841).

**Supplemental Table 5c:**

|  |  |  |
| --- | --- | --- |
| **Variable** | **HR (95% CI)** | **p-value** |
| Age (Numeric) | 0.996 (0.985 to 1.01) | 0.419 |
| Female | 0.714 (0.535 to 0.95) | 0.0221 |
| BMI | 1.02 (0.999 to 1.04) | 0.0682 |
| Current or Former Smoker | 1.05 (0.883 to 1.24) | 0.601 |
| Coronary Artery Disease | 0.858 (0.555 to 1.33) | 0.492 |
| Congestive Heart Failure | 0.812 (0.594 to 1.11) | 0.192 |
| History of Stroke | 0.96 (0.571 to 1.62) | 0.879 |
| Diabetes Mellitus | 1.12 (0.839 to 1.49) | 0.444 |
| Hypertension | 1.59 (1.1 to 2.3) | 0.0141 |
| Cirrhosis | 1.16 (0.385 to 3.5) | 0.791 |
| HIV | 1.05 (0.455 to 2.4) | 0.917 |
| Inflammatory Bowel Disease | 0.337 (0.0466 to 2.43) | 0.28 |
| Pulmonary Disease | 1.07 (0.771 to 1.48) | 0.698 |
| Renal Disease | 0.695 (0.44 to 1.1) | 0.118 |
| Viral Hepatitis | 0.942 (0.349 to 2.54) | 0.905 |
| Cancer | 0.654 (0.33 to 1.3) | 0.224 |
| Transplant History | 1.03 (0.525 to 2.04) | 0.923 |
| Rheumatological Disease | 1.09 (0.54 to 2.18) | 0.816 |
| Immunosuppressed State | 0.959 (0.328 to 2.8) | 0.94 |
| No Comorbidities | 0.999 (0.562 to 1.77) | 0.997 |


**Supplemental Table 5c Cox Proportional Hazard Model for Intubation or Death** Hazard ratio of intubation or death for demographics and comorbidities with 95% confidence intervals and corresponding p-values. Only patients with complete data for all of the above variables were included in the model (n = 841).

**Supplemental Figure 1**



**Supplemental Figure 1 Distribution of Time from ED Arrival to First Intubation** The time from ED arrival to intubation for n = 225 patients is visualized for patients who have reached the point of intubation at least once. 71.6% of patients are intubated within the first three days.

**Supplemental Figure 2**



**Supplemental Figure 2 Days from First Symptom to First Intubation vs. ED Date:** 136 patients had a recorded date for first symptom onset. These patients are visualized in this figure with time symptom onset to first intubation plotted against the date of ED arrival.